Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

@article{Trimble2015SafetyEA,
  title={Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.},
  author={Cornelia Liu Trimble and Matthew P. Morrow and Kimberly A. Kraynyak and Xuefei Shen and Michael Dallas and Jian Yan and Lance Edwards and Rachel L. Parker and Lynnette E. Denny and Mary D Giffear and Ami Shah Brown and Kathleen Marcozzi-Pierce and Divya P. Shah and Anna M Slager and Albert J Sylvester and Amir Sultan Khan and Kate E Broderick and Robert J Juba and Timothy A Herring and Jean D. Boyer and Jessica C Lee and Niranjan Y Sardesai and David B. Weiner and Mark L. Bagarazzi},
  journal={Lancet},
  year={2015},
  volume={386 10008},
  pages={2078-2088}
}
BACKGROUND Despite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can lead to long-term reproductive morbidity. We assessed whether VGX-3100, synthetic plasmids targeting HPV-16 and HPV-18 E6 and E7 proteins, delivered by electroporation, would cause histopathological regression in women with CIN2/3. METHODS Efficacy, safety, and immunogenicity of VGX-3100 were assessed in CIN2/3… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 120 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 100 extracted citations

Similar Papers

Loading similar papers…